Shu Ling Zhang

Shu Ling Zhang

Auto-generated profile, based on publicly available information

Shu Ling Zhang

Department of Neurology, Zhengzhou People's Hospital, Zhengzhou 450003, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
LSLiang Song
Liang Song
MXMeng-Bei Xu
Meng-Bei Xu
XZXiao-Li Zhou
Xiao-Li Zhou
DZDao-Pei Zhang
Dao-Pei Zhang
SZShu-Ling Zhang
Shu-Ling Zhang
GZGq_Zheng Zheng
Gq_Zheng Zheng
To date, no drug has been proven to be neuroprotective or disease‐modifying for Parkinson’s disease (PD) in clinical trials. Here, we aimed to assess preclinical evidence of Ginsenosides‐Rg1 (G‐Rg1), a potential neuroprotectant, for experimental PD and its possible mechanisms. Eligible studies were identified by searching six electronic databases from their inception to August 2016. Twenty‐five eligible studies involving 516 animals were identified. The quality score of these studies ranged from 3 to 7. Compared with the control group, two out of the 12 studies of MPTP‐induced PD showed significant effects of G‐Rg1 for improving the rotarod test (P < 0.01), two studies for improving the swim‐score values (P < 0.01), six studies for improving the level of TH protein expression (P < 0.01), and two studies for increasing the expression of TH mRNA in the substantia nigra of mice (P < 0.01). The studies reported that G‐Rg1 exerted potential neuroprotective effects on PD model through different mechanisms as antineuroinflammatory activities (n = 10), antioxidant stress (n = 3), and antiapoptosis (n = 11). In conclusion, G‐Rg1 exerted potential neuroprotective functions against PD largely by antineuroinflammatory, antioxidative, and antiapoptotic effects. G‐Rg1 as a promising neuroprotectant for PD needs further confirmation by clinical trials.

1 March 2014 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
DZDao-Pei Zhang
Dao-Pei Zhang
SZShu-Ling Zhang
Shu-Ling Zhang
JZJiewen Zhang
Jiewen Zhang
HZHong-Tao Zhang
Hong-Tao Zhang
SFSheng-Qi Fu
Sheng-Qi Fu
PJPeng Ji
Peng Ji

1 September 2017 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
JSJohn K. Simmons
John K. Simmons
AMAleksandra M Michalowski
Aleksandra M Michalowski
BGBenjamin J. Gamache
Benjamin J. Gamache
WDWendy DuBois
Wendy DuBois
JPJyoti Patel
Jyoti Patel
BMBeverly Mock
Beverly Mock
Cancer treatments often require combinations of molecularly targeted agents to be effective. mTORi (rapamycin) and HDACi (MS-275/entinostat) inhibitors have been shown to be effective in limiting tumor growth, and here we define part of the cooperative action of this drug combination. More than 60 human cancer cell lines responded synergistically (CI<1) when treated with this drug combination compared with single agents. In addition, a breast cancer patient–derived xenograft, and a BCL-XL plasmacytoma mouse model both showed enhanced responses to the combination compared with single agents. Mice bearing plasma cell tumors lived an average of 70 days longer on combination treatment compared with single agents. A set of 37 genes cooperatively affected (34 downregulated; 3 upregulated) by the combination responded pharmacodynamically in human myeloma cell lines, xenografts, and a P493 model, and were both enriched in tumors, and correlated with prognostic markers in myeloma patient datasets. Genes downregulated by the combination were overexpressed in several untreated cancers (breast, lung, colon, sarcoma, head and neck, myeloma) compared with normal tissues. The MYC/E2F axis, identified by upstream regulator analyses and validated by immunoblots, was significantly inhibited by the drug combination in several myeloma cell lines. Furthermore, 88% of the 34 genes downregulated have MYC-binding sites in their promoters, and the drug combination cooperatively reduced MYC half-life by 55% and increased degradation. Cells with MYC mutations were refractory to the combination. Thus, integrative approaches to understand drug synergy identified a clinically actionable strategy to inhibit MYC/E2F activity and tumor cell growth in vivo. Mol Cancer Ther; 16(9); 2008–21. ©2017 AACR.

3 December 2013 in Molecular Oncology
Verified
Journal Article
Open access
JSJohn K. Simmons
John K. Simmons
JPJyoti Patel
Jyoti Patel
AMAleksandra M Michalowski
Aleksandra M Michalowski
SZShuling Zhang
Shuling Zhang
BWBih-Rong Wei
Bih-Rong Wei
BMBeverly Mock
Beverly Mock
Enhanced proliferative signaling and loss of cell cycle regulation are essential for cancer progression. Increased mitogenic signaling through activation of the mTOR pathway, coupled with deregulation of the Cyclin D/retinoblastoma (Rb) pathway is a common feature of lymphoid malignancies, including plasmacytoma (PCT), multiple myeloma (MM), Burkitt's lymphoma (BL), and mantle cell lymphoma (MCL). Here we evaluate the synergy of pharmacologically affecting both of these critical pathways using the mTOR inhibitor sirolimus and the histone deacetylase inhibitor entinostat. A dose‐matrix screening approach found this combination to be highly active and synergistic in a panel of genetically diverse human MM cell lines. Synergy and activity was observed in mouse PCT and human BL and MCL cell lines tested in vitro, as well as in freshly isolated primary MM patient samples tested ex vivo. This combination had minimal effects on healthy donor cells and retained activity when tested in a co‐culture system simulating the protective interaction of cancer cells with the tumor microenvironment. Combining sirolimus with entinostat enhanced cell cycle arrest and apoptosis. At the molecular level, entinostat increased the expression of cell cycle negative regulators including CDKN1A (p21) and CDKN2A (p16), while the combination decreased critical growth and survival effectors including Cyclin D, BCL‐XL, BIRC5, and activated MAPK.

16 January 2014 in BMC Neurology
Verified
Journal Article
Open access
PDF file
ZHZhang Hong-Tao
Zhang Hong-Tao
ZSZhang Shu-Ling
Zhang Shu-Ling
DZDaopei Zhang
Daopei Zhang
Background: Tortuous blood vessels are commonly seen in the cerebral arteries. The association between vertebrobasilar artery tortuosity and vascular vertigo remains obscure. Case presentation: We describe two patients with vascular vertigo who had bilateral curving and spiral looping in multiple segments of the vertebral arteries and also exhibited basilar artery tortuosity. Both patients had cerebrovascular risk factors and exhibited clinical features of vertigo with high severity, slow recovery, and recurrent tendencies. Contrast enhanced magnetic resonance angiography of the neck showed bilateral tortuosity in the V2 segments and spiral twisting in the V4 segments of the vertebral arteries, and basilar artery curving. No obvious sign of atherosclerotic stenosis was found in the vertebrobasilar arteries and no abnormalities were observed in the internal carotid arteries. Transcranial Doppler ultrasound showed decreased blood flow in tortuous vertebrobasilar arteries. Brainstem auditory evoked potentials showed that the interpeak latencies (IPL) of waves III-IV were prolonged, with a ratio of IPL III-V/IPL I-III > 1. Conclusions: Vertebrobasilar tortuosity in combination with cerebrovascular risk factors may lead to vascular vertigo in these patients.

1 September 2016 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
DZDao Pei Zhang
Dao Pei Zhang
QMQian Kun Ma
Qian Kun Ma
JZJiewen Zhang
Jiewen Zhang
SZShu Ling Zhang
Shu Ling Zhang
GLGui Feng Lu
Gui Feng Lu
SYSuo Yin
Suo Yin